NASDAQ:CFRX

ContraFect - CFRX Stock Forecast, Price & News

$0.17

0.00 (0.00%)

(As of 10/3/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.16
▼
$0.17
50-Day Range: $0.17
▼
$0.35
52-Week Range: $0.16
▼
$4.54

Volume: 881,555 shs
Average Volume: 879,102 shs
Market Capitalization: $6.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

ContraFect MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 2,523.9% Upside
$4.50 Price Target
Short Interest: Healthy
0.89% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.72
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.34) to ($1.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
ContraFect has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.50, ContraFect has a forecasted upside of 2,523.9% from its current price of $0.17.
Amount of Analyst Coverage
ContraFect has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.89% of the float of ContraFect has been sold short.
Short Interest Ratio / Days to Cover
ContraFect has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ContraFect has recently decreased by 7.17%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ContraFect does not currently pay a dividend.
Dividend Growth
ContraFect does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CFRX.

2.1

News and Social Media Coverage

News Sentiment
ContraFect has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for ContraFect this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for CFRX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added ContraFect to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ContraFect insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.60% of the stock of ContraFect is held by insiders.
Percentage Held by Institutions
63.80% of the stock of ContraFect is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ContraFect are expected to grow in the coming year, from ($1.34) to ($1.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ContraFect is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ContraFect is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ContraFect has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ContraFect (NASDAQ:CFRX) Stock

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Stock News Headlines

October 2, 2022 | americanbankingnews.com

Analysts Set ContraFect Co. (NASDAQ:CFRX) Target Price at $4.50

September 27, 2022 | americanbankingnews.com

StockNews.com Begins Coverage on ContraFect (NASDAQ:CFRX)

September 14, 2022 | uk.investing.com

Why Kaspien Holdings Is Trading Lower By 13%; Here Are 21 Stocks Moving Premarket By Benzinga - Investing.com UK

September 12, 2022 | finance.yahoo.com

ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections - Yahoo Finance

September 12, 2022 | baystreet.ca

ContraFect Retreats on Publication

September 12, 2022 | globenewswire.com

ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections - GlobeNewswire

September 12, 2022 | finance.yahoo.com

ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection

September 12, 2022 | finance.yahoo.com

ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections

September 9, 2022 | streetinsider.com

Form SC 13G/A CONTRAFECT Corp Filed by: FEDERATED HERMES, INC. - StreetInsider.com

September 7, 2022 | benzinga.com

ContraFect (CFRX) – CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis… - Benzinga

September 6, 2022 | reuters.com

CFRX.A - ContraFect Corp | Stock Price & Latest News | Reuters

September 1, 2022 | finance.yahoo.com

CFRX: Exebacase Shows Potent Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis…

August 23, 2022 | finance.yahoo.com

ContraFect Cuts Workforce After Trial Setback

August 17, 2022 | finance.yahoo.com

ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Yahoo Finance

August 16, 2022 | morningstar.com

Tech startup layoffs approach 71000 in 2022 - Morningstar

August 16, 2022 | benzinga.com

ContraFect: Q2 Earnings Insights - Benzinga

August 16, 2022 | marketwatch.com

Tech startup layoffs approach 71,000 in 2022 - MarketWatch

August 16, 2022 | finance.yahoo.com

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis - Yahoo Finance

August 15, 2022 | seekingalpha.com

Contrafect GAAP EPS of -$0.46 misses by $0.13 (NASDAQ:CFRX) - Seeking Alpha

August 15, 2022 | benzinga.com

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activ - Benzinga

August 15, 2022 | globenewswire.com

ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire

August 15, 2022 | finance.yahoo.com

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis

August 15, 2022 | finance.yahoo.com

ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022 | businesswire.com

Zephyr AI Announces Additions to the Board of Directors - Business Wire

August 5, 2022 | reuters.com

CFRX.OQ - ContraFect Corp | Stock Price & Latest News | Reuters

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Company Calendar

Last Earnings: 8/15/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/21/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CFRX
CUSIP: N/A
CIK: 1478069
Web: www.contrafect.com
Phone: (914) 207-2300
Fax: N/A
Employees: 38
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.50
High Stock Price Forecast: $9.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +2,523.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.21)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -131.83%
Return on Assets: -79.32%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.83
Quick Ratio: 1.83

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.26 per share
Price / Book: 0.14

Miscellaneous

Outstanding Shares: 39,333,000
Free Float: 37,917,000
Market Cap: $6.75 million
Optionable: Not Optionable
Beta: 0.30

Key Executives

Dr. Roger James Pomerantz F.A.C.P. (Age 65)
FACP, M.D., Chairman, CEO & Pres
Comp: $1.27M

Mr. Michael Messinger CPA (Age 47)
CPA, Chief Financial Officer
Comp: $620.25k

Ms. Natalie Bogdanos J.D. (Age 53)
Gen. Counsel, Corp. Sec. & Data Protection Officer

Mr. Matthew Salamone P.H.R.
SPHR, VP of HR

Dr. Gary Woodnutt (Age 65)
Sr. VP of Translational Sciences & Preclinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CFRX Stock - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?: 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 3 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings or view top-rated stocks.
What is ContraFect's stock price forecast for 2022?: 5 equities research analysts have issued 12-month price objectives for ContraFect's stock. Their CFRX share price forecasts range from $1.00 to $9.00. On average, they anticipate the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 2,517.8% from the stock's current price.
View analysts price targets for CFRX or view top-rated stocks among Wall Street analysts.
How have CFRX shares performed in 2022?: ContraFect's stock was trading at $2.63 on January 1st, 2022. Since then, CFRX shares have decreased by 93.5% and is now trading at $0.1719.
View the best growth stocks for 2022 here.
When is ContraFect's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our CFRX earnings forecast.
How were ContraFect's earnings last quarter?: ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.17.

When did ContraFect's stock split?: ContraFect shares reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What other stocks do shareholders of ContraFect own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).
What is ContraFect's stock symbol?: ContraFect trades on the NASDAQ under the ticker symbol "CFRX."
How do I buy shares of ContraFect?: Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is ContraFect's stock price today?: One share of CFRX stock can currently be purchased for approximately $0.17.
How much money does ContraFect make?: ContraFect (NASDAQ:CFRX) has a market capitalization of $6.76 million. The biotechnology company earns $-20,280,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.
How can I contact ContraFect?: ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.

This page (NASDAQ:CFRX) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ContraFect - CFRX Stock Forecast, Price & News

ContraFect MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ContraFect (NASDAQ:CFRX) Stock

CFRX Stock News Headlines

CFRX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CFRX Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™